¥ 1,049
+7.5 (+0.72%)
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
| Asset | Price | 1Y Change | Market Cap | PER | PBR | Div. Yield |
|---|---|---|---|---|---|---|
2160 GNI Group Ltd. | ¥2,993+5.72% | +19.77% | 1671B JPY | — | 4.1x | 0.00% |
4547 KISSEI PHARMACEUTICAL CO.,LTD. | ¥4,020+0.25% | -8.53% | 1666B JPY | 11.9x | 0.7x | 4.23% |
4521 KAKEN PHARMACEUTICAL CO.,LTD. | ¥4,005+2.17% | +4.03% | 1517B JPY | 14.7x | 1.0x | 4.74% |
4587Current PeptiDream Inc. | ¥1,049+0.72% | -37.60% | 1349B JPY | — | 2.8x | 0.00% |
4534 Mochida Pharmaceutical Co.,Ltd. | ¥3,330+1.83% | +3.90% | 1177B JPY | 12.8x | 0.8x | 2.55% |
4565 Nxera Pharma Co.,Ltd. | ¥1,266+5.94% | +27.36% | 1157B JPY | — | 1.8x | 0.00% |
4559 ZERIA PHARMACEUTICAL CO.,LTD. | ¥2,032+1.20% | -3.19% | 896B JPY | 10.9x | 0.8x | 2.46% |